UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

		M 10-Q/A ndment No. 1)	
☑ QUARTERLY REPO ACT OF 1934	ORT PURSUANT TO SI	ECTION 13 OR 15(d) OF TI	HE SECURITIES EXCHANGE
	for the quarterly peri	od ended September 30, 2015	
		OR	
☐ TRANSITION REPO ACT OF 1934	ORT PURSUANT TO SI	ECTION 13 OR 15(d) OF TI	HE SECURITIES EXCHANGE
	for the transition pe	riod from to .	
	COMMISSION FI	ILE NUMBER: 001-37590	
		ecor Inc. rant as specified in its charter)	
DELAW (State of inco			5-0705648 yer Identification No.)
400 E. Pratt Stre Baltimore, Mar (Address of Principal including Z	ryland 21202 Executive Offices, ip Code)	(Registrant's Includi	0) 522-8707 5 Telephone Number, ing Area Code) y Section 13 or 15(d) of the Securities
	receding 12 months (or for suc	ch shorter period that the registrant	was required to file such reports), and
		ents for the past 90 days as it commired to be filed by Section 13 or 15	nenced trading following its initial (d) of the Securities Exchange Act of
Indicate by check mark what Interactive Data File required to be preceding 12 months (or for such shapes)	submitted and posted pursuan		232.405 of this chapter) during the
			er, a non-accelerated filer, or a smaller reporting company" in Rule 12b-2 of
Large accelerated filer	Accelerated filer □	Non-accelerated filer □	Smaller reporting company X

EXPLANATORY NOTE

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \square No \boxtimes

(Do not check if a smaller reporting company)

As of November 13, 2015, the registrant had 8,630,143 shares of common stock outstanding.

Form 10-Q for the quarter ended September 30, 2015 (the "Form 10-Q"), filed with the U.S. Securities and Exchange Commission on November 13, 2015, solely to correct an error set forth in Part II, Item 2, "Unregistered Sales of Equity Securities and Use of Proceeds" of the Form 10-Q and to include a signature page to the Form 10-Q. Part II, Item 2 of the Form 10-Q incorrectly stated that the underwriter of the Company's initial public offering ("IPO") exercised its over-allotment option for another 600,000 Units for additional gross proceeds of \$3,900,000 when such exercise had not occurred and the signature page to the Form 10-Q was inadvertently omitted. Amendment No. 1 correctly omits any discussion with respect to the exercise of the over-allotment option in connection with the Company's IPO and includes a signature page of the Company.

As required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended, the Company is also filing as exhibits to Amendment No. 1 the certifications required under Section 302 of the Sarbanes-Oxley Act of 2002.

This Amendment No. 1 should be read in conjunction with the original Form 10-Q, which continues to speak as of the date of the Form 10-Q. Except as specifically noted above, this Amendment No. 1 does not modify or update disclosures in the original Form 10-Q. Accordingly, this Amendment No. 1 does not reflect events occurring after the filing of the Form 10-Q or modify or update any related or other disclosures.

2

PART II — OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds from Registered Securities.

Pursuant to the Registration Statement on Form S-1 (File No. 333-204905), as amended, that was declared effective by the SEC on October 14, 2015, we registered the Units to be sold in the IPO (including 600,000 Units with respect to an over-allotment option granted by us to the underwriters in the Offering).

We sold a total of 4,000,000 units in the IPO at an initial public offering price per unit of \$6.50 for gross proceeds of \$26,000,000. The net proceeds of the IPO, before offering expenses, to the Company were approximately \$23.6 million, determined as follows:

	Total
Initial public offering price	\$ 26,000,000
Underwriting discounts and commissions	(1,950,000)
Non-accountable expense allowance	(390,000)
Underwriting legal fees	(100,000)
	\$ 23,560,000

We will use the proceeds of this offering together with our cash and cash equivalents to fund the cost of our Phase 2 clinical development programs for CERC-301 and CERC-501, to fund research and development to advance our preclinical lead candidates under the COMTi platform and for working capital, general corporate purposes and potential in-licensing or other acquisitions.

No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates. There has been no material change in the planned use of proceeds from our IPO as described in our IPO Prospectus.

Item 6. EXHIBITS

Exhibit		Incorporated by Reference			Filed
No.	Exhibit Description	Form	Date	Number	Herewith
3.1	Amended and Restated Certificate of Incorporation of Cerecor				
	Inc.	S-1	6/12/15	3.1	
3.2	Bylaws of Cerecor Inc., as currently in effect.	S-1	6/12/15	3.3	
4.1	Form of Unit Purchase Option	S-1/A	10/13/15	4.8	
4.2	Form of Class A Warrant Agreement	S-1/A	10/13/15	4.9	
4.3	Specimen Class A Warrant Certificate	S-1/A	10/13/15	4.10	
4.4	Form of Class B Warrant Agreement	S-1/A	10/13/15	4.11	
4.5	Specimen Class B Warrant Certificate	S-1/A	10/13/15	4.12	
10.2	Cerecor Inc. 2015 Omnibus Incentive Plan, including form of				
	Nonqualified Stock Option Agreements thereunder	S-1/A	9/8/2015	10.5	
31.1	Certification of Chief Executive Officer (Principal Executive				
	Officer) pursuant to Rule 13a-14(a)/15d-14(a), as adopted				
	pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X
31.2	Certification of Chief Financial Officer (Principal Financial				
	Officer) pursuant to Rule 13a-14(a)/15d-14(a), as adopted				

	pursuant to Section 302 of the Sarbanes-Oxley Act of 2002			X	
32.1	Certification of the Chief Executive Office (Principal Executive				
	Officer) and Chief Financial Officer (Principal Financial				
	Officer)pursuant to 18 U.S.C. Section 1350, as adopted pursuant				
	to Section 906 of the Sarbanes-Oxley Act of 2002	10-Q	11/13/15		
101.INS	XBRL Instance Document	10-Q	11/13/15		
101.SCH	XBRL Taxonomy Extension Schema Document	10-Q	11/13/15		
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	10-Q	11/13/15		
101.DEF	XBRL Taxonomy Extension Definition Linkbase	10-Q	11/13/15		
101.LAB	XBRL Taxonomy Extension Label Linkbase	10-Q	11/13/15		
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	10-Q	11/13/15		
3					

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CERECOR INC.

Date: November 23, 2015 By: /s/ MARIAM M. MORRIS

Name: Mariam M. Morris
Title: Chief Financial Officer
(Principal Executive Officer)

4

CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Blake M. Paterson, certify that:

- 1. I have reviewed this Quarterly Report on Amendment No. 1 to the Quarterly Report on Form 10-Q/A of Cerecor Inc.; and
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date November 23, 2015

/s/ Blake M. Paterson

Blake M. Paterson Chief Executive Officer Principal Executive Officer

1

CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mariam E. Morris, certify that:

- 1. I have reviewed this Quarterly Report on Amendment No. 1 to the Quarterly Report on Form 10-Q/A of Cerecor Inc.; and
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date November 23, 2015

/s/ Mariam E. Morris

Mariam E. Morris Chief Financial Officer

Principal Financial and Accounting Officer

1